Gleamer raises €27 million in a Series B funding round to expand its AI medical imaging solutions and strengthen its international presence.

Target Information

Gleamer, a European leader in artificial intelligence (AI) solutions for medical imaging, has successfully raised €27 million in a Series B funding round. This investment round was led by Supernova Invest, followed by Heal Capital and participation from various historical partners, including XAnge, Elaia, Bpi France via the F3A and Digital Venture funds, MACSF, Crista Galli Ventures, UI Investissement, and several European radiologists. The total funds raised to date amount to €35 million, which comprises €7.5 million from Series A in 2020 and €1.5 million from a seed funding round in 2018. The new funding will empower Gleamer to broaden its solution portfolio, enhance its teams in Europe and the U.S., and accelerate its international commercial development.

Since its inception, Gleamer has developed a comprehensive suite of CE marked class IIa AI solutions for standard radiography, achieving two FDA clearances as well. These clinical diagnostic solutions have gained global recognition within the scientific community, evidenced by nine publications in major medical journals. Currently, Gleamer's technology is utilized by over 6,500 users across 650 sites in 24 countries, processing more than one million medical examinations each month. This recent funding will provide Gleamer with the necessary resources to achieve its strategic objectives and facilitate the large-scale deployment of innovative technological solutions that meet the needs of medical professionals worldwide.

Industry Overview

In recent years, the medical imaging industry has started embracing artificial intelligence as a transformative technology that enhances diagnostic accuracy and workflow efficiency. As healthcare systems worldwide continue to grapple with increasing patient volumes and the demand for superior ca